GenomiX: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
GenomiX
Largest movements
- Financial fixed assets +€10,000
up €10,000 (+3.0%), from €328,077 to €338,077
- Profit (loss) carried forward +€9,134
up €9,134 (+42.7%), from €21,391 to €30,524
- Gross operating margin +€205
up €205 (+15.6%), from -€1,314 to -€1,109
- Financial charges +€144
up €144 (+5.3%), from €2,721 to €2,865
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €332,295 | €343,875 | +€11,580 | +3.5% |
| Fixed assets | 21/28 | €328,077 | €338,077 | +€10,000 | +3.0% |
| Financial fixed assets | 28 | €328,077 | €338,077 | +€10,000 | +3.0% |
| Current assets | 29/58 | €4,218 | €5,798 | +€1,580 | +37.5% |
| Cash at bank and in hand | 54/58 | €4,218 | €5,798 | +€1,580 | +37.5% |
| Total equity and liabilities | 10/49 | €332,295 | €343,875 | +€11,580 | +3.5% |
| Equity | 10/15 | €246,391 | €255,524 | +€9,134 | +3.7% |
| Contributions | 10/11 | €225,000 | €225,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €21,391 | €30,524 | +€9,134 | +42.7% |
| Amounts payable | 17/49 | €85,904 | €88,350 | +€2,446 | +2.8% |
| Amounts payable after more than one year | 17 | €47,825 | €47,825 | = | 0.0% |
| Other amounts payable | 178/9 | €47,825 | €47,825 | = | 0.0% |
| Amounts payable within one year | 42/48 | €31,378 | €31,109 | -€269 | -0.9% |
| Trade debts | 44 | €1,378 | €1,109 | -€269 | -19.5% |
| Suppliers | 440/4 | €1,378 | €1,109 | -€269 | -19.5% |
| Other amounts payable | 47/48 | €30,000 | €30,000 | = | 0.0% |
| Accrued charges and deferred income | 492/3 | €6,701 | €9,416 | +€2,715 | +40.5% |
| Other operating charges | 640/8 | €607 | €620 | +€12 | +2.0% |
| Non-recurring operating charges | 66A | - | €50 | +€50 | |
| Gross operating margin | 9900 | -€1,314 | -€1,109 | +€205 | +15.6% |
| Operating profit (loss) | 9901 | -€1,922 | -€1,779 | +€142 | +7.4% |
| Financial income | 75/76B | €13,778 | €13,778 | = | 0.0% |
| Recurring financial income | 75 | €13,778 | €13,778 | = | 0.0% |
| Financial charges | 65/66B | €2,721 | €2,865 | +€144 | +5.3% |
| Recurring financial charges | 65 | €2,721 | €2,865 | +€144 | +5.3% |
| Profit (loss) for the period before taxes | 9903 | €9,135 | €9,134 | -€2 | 0.0% |
| Profit (loss) for the period | 9904 | €9,135 | €9,134 | -€2 | 0.0% |
| Profit (loss) for the period to be appropriated | 9905 | €9,135 | €9,134 | -€2 | 0.0% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 12 October 2026 via checked.be.